Search results for "ADE"

showing 10 items of 15269 documents

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

2019

Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effecti…

0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsTumour heterogeneityReceptor ErbB-2DiseaseDrug resistanceAdenocarcinomaGastroesophageal Junction AdenocarcinomaGenetic Heterogeneity03 medical and health sciences0302 clinical medicineStomach NeoplasmsTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPrecision Medicineskin and connective tissue diseasesGastroesophageal adenocarcinomabusiness.industryGene AmplificationHematologyPrognosisPrecision medicineProgression-Free SurvivalBlockade030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisEsophagogastric Junctionbusinessmedicine.drugAnnals of Oncology
researchProduct

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy

2018

Esophageal cancer (EC) is one of the most lethal cancers and a public health concern worldwide, owing to late diagnosis and lack of efficient treatment. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are main histopathological subtypes of EC that show striking differences in geographical distribution, possibly due to differences in exposure to risk factors and lifestyles. ESCC and EAC are distinct diseases in terms of cell of origin, epidemiology, and molecular architecture of tumor cells. Past efforts aimed at translating potential molecular candidates into clinical practice proved to be challenging, underscoring the need for identifying novel candidates for …

0301 basic medicineOncologymedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentEarly detectionGenomicsDiseaseAdenocarcinomaGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHistory and Philosophy of ScienceInternal medicineEpidemiologyHumansMedicineEarly Detection of CancerEpigenomicsbusiness.industryGeneral NeuroscienceEpigenomeImmunotherapyEsophageal cancermedicine.disease030104 developmental biology030220 oncology & carcinogenesisMutationEsophageal Squamous Cell CarcinomabusinessAnnals of the New York Academy of Sciences
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct

La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques

2017

The role of the immune response in breast cancer is now well recognized and increasingly taken in account. The goal of this article is, in the first part, to underline its prognostic impact and to precise the immunosurvelliance, immunoselection and the immunosubversion concepts involved in the control and evasion of breast carcinoma. In the second part, therapeutic strategies for the restauration of anti-tumor immunity are developed. Vaccination strategies and checkpoints inhibitors blockade strategies are discussed as well as the immunogenic death linked to the conventional treatments of breast cancer.

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunotherapymedicine.disease3. Good healthPathology and Forensic MedicineBlockadeImmunosurveillanceVaccination03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerImmune systemTumor Escape030220 oncology & carcinogenesisInternal medicinemedicineBreast carcinomabusinessAnnales de Pathologie
researchProduct

Multi-criteria framework as an innovative tradeoff approach to determine the shelf-life of high pressure-treated poultry

2016

International audience; A multi-criteria framework combining safety, hygiene and sensorial quality was developed to investigate the possibility of extending the shelf-life and/or removing lactate by applying High Hydrostatic Pressure (HHP) in a ready-to-cook (RTC) poultry product. For this purpose, Salmonella and Listeria monocytogenes were considered as safety indicators and Escherichia coli as hygienic indicator. Predictive modeling was used to determine the influence of HHP and lactate concentration on microbial growth and survival of these indicators. To that end, probabilistic assessment exposure models developed in a previous study (Lerasle, M., Guillou, S., Simonin, H., Anthoine, V.,…

0301 basic medicineOrganolepticHydrostatic pressureSodium lactateEscherichia-coliPoultrylLsteria-monocytogenesInactivationchemistry.chemical_compoundSalmonella[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceCookingPoultry ProductsPotassium lactateMathematics2. Zero hungerHigh hydrostatic-pressurePoultry product[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringRisk-risk trade-off;Lactate;Food hygiene;Food safety;Sensorial qualitySensorial qualityRisk-risk trade-off04 agricultural and veterinary sciencesGeneral Medicine040401 food scienceMeat ProductsCured beef carpaccioTasteIn-ground beefMeat-products030106 microbiologyShelf lifeMicrobiologyFood safety03 medical and health sciences0404 agricultural biotechnologyChicken meatFood PreservationEscherichia coliHydrostatic PressureFood hygieneFood microbiologyAnimalsHumansExposure assessmentbusiness.industryDifferent temperaturesFood safetyListeria monocytogeneschemistryFood StorageConsumer Product SafetyLactatebusinessFood Science
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

Modified Vitrectomy Technique for Phakic Rhegmatogenous Retinal Detachment with Intermediate Break

2018

Purpose. To evaluate the effects of a modification of the traditional 25-gauge pars plana vitrectomy technique in the treatment of uncomplicated macula-on rhegmatogenous retinal detachment (RRD) with intermediate retinal break(s) and marked vitreous traction in the phakic eye. Methods. Prospective, noncomparative, and interventional case series. All consecutive phakic eyes with primary uncomplicated macula-on RRD with intermediate retinal break(s) and marked vitreous traction, with at least 1 year of postoperative follow-up, were enrolled. In all eyes, “localized 25-gauge vitrectomy” under air infusion with localized removal of the vitreous surrounding the retinal break(s), in association w…

0301 basic medicinePars planamedicine.medical_specialtygenetic structuresArticle Subjectmedicine.medical_treatmentScheimpflug principlevitrectomyVitrectomy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:OphthalmologyOphthalmologymedicineMacular edemabusiness.industryRetinal detachmentRetinalmedicine.diseaseeye diseasesOphthalmology030104 developmental biologymedicine.anatomical_structurechemistrylcsh:RE1-994030221 ophthalmology & optometryClinical StudyTamponadesense organsEpiretinal membranebusiness
researchProduct

Quantitative immunomorphological analysis of heat shock proteins in thyroid follicular adenoma and carcinoma tissues reveals their potential for diff…

2019

Hsp27, Hsp60, Hsp70, and Hsp90 are chaperones that play a crucial role in cellular homeostasis and differentiation, but they may be implicated in carcinogenesis. Follicular neoplasms of the thyroid include follicular adenoma and follicular carcinoma. The former is a very frequent benign encapsulated nodule, whereas the other is a nodule that infiltrates the capsule, blood vessels and the adjacent parenchyma, with a tendency to metastasize. The main objective was to assess the potential of the Hsps in differential diagnosis and carcinogenesis. We quantified by immunohistochemistry Hsp27, Hsp60, Hsp70, and Hsp90 on thin sections of human thyroid tissue with follicular adenoma or follicular ca…

0301 basic medicinePathologyCellular homeostasismedicine.disease_causechaperonopathieslcsh:TechnologyHsp70lcsh:Chemistry0302 clinical medicineFollicular phasedifferential diagnosisGeneral Materials ScienceHsp27Instrumentationlcsh:QH301-705.5CarcinogenesiFluid Flow and Transfer ProcessesThyroidThyroidGeneral EngineeringHsp60Follicular adenomalcsh:QC1-999Computer Science Applicationsmedicine.anatomical_structure030220 oncology & carcinogenesisMolecular chaperoneImmunohistochemistrycarcinogenesismedicine.medical_specialtyendocrine systemanimal structuresAdenomaDifferential diagnosiHsp90BiologyFollicular carcinoma03 medical and health sciencesParenchymaCarcinomamedicinelcsh:TProcess Chemistry and Technologymedicine.disease030104 developmental biologylcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040ChaperonopathieCarcinogenesislcsh:Engineering (General). Civil engineering (General)lcsh:Physics
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors

2017

Ewing sarcoma is an aggressive neoplasm of pediatric and adolescent patients. Immunohistochemistry (IHC) can be used to support the morphologic diagnosis of Ewing sarcoma family of tumors (ESFT) in a convincing clinical/radiological context. Although neither NKX2.2 nor CD99 alone are entirely specific, when combined, the diagnostic specificity is high. The aim of the present study was to investigate the IHC expression of NKX2.2, ETV4 and BCOR in a large series of genetically confirmed ESFT. The results for CD99 and CAV-1 immunoreactivity, and the histological and fusion gene subtypes were retrieved from our previous study. NKX2.2 demonstrated moderate or strong nuclear positivity in 91.2% o…

0301 basic medicinePathologymedicine.medical_specialtyCD99Bone NeoplasmsContext (language use)Sarcoma EwingBiologyPathology and Forensic MedicineFusion gene03 medical and health sciences0302 clinical medicineProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasmHomeodomain ProteinsProto-Oncogene Proteins c-etsNuclear ProteinsCell BiologyZebrafish Proteinsmedicine.diseaseImmunohistochemistryRepressor ProteinsHomeobox Protein Nkx-2.2030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinImmunohistochemistryAdenovirus E1A ProteinsSarcomaMorphologic diagnosisAntibodyTranscription FactorsPathology - Research and Practice
researchProduct